Goldman Sachs
CLYM

Goldman Sachs’s Climb Bio CLYM Stock Holding History

Goldman Sachs’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Sell
83,230
-66,740
-45% -$689K ﹤0.01% 5146
2026
Q1 		$1.03M Sell
149,970
-74,913
-33% -$432K ﹤0.01% 5069
2025
Q4 		$900K Buy
224,883
+151,168
+205% +$363K ﹤0.01% 5215
2025
Q3 		$148K Sell
73,715
-127,597
-63% -$237K ﹤0.01% 6008
2025
Q2 		$250K Buy
201,312
+80,570
+67% +$100K ﹤0.01% 5547
2025
Q1 		$147K Sell
120,742
-4,562
-4% -$7.4K ﹤0.01% 5707
2024
Q4 		$226K Buy
125,304
+66,258
+112% +$240K ﹤0.01% 5598
2024
Q3 		$301K Buy
+59,046
New +$418K ﹤0.01% 5297
2022
Q3 		– Sell
-162,792
Closed -$492K – 6582
2022
Q2 		$492K Sell
162,792
-2,295
-1% -$10.9K ﹤0.01% 5091
2022
Q1 		$1.39M Buy
165,087
+964
+0.6% +$8.99K ﹤0.01% 4562
2021
Q4 		$1.72M Sell
164,123
-1,829
-1% -$27.3K ﹤0.01% 4379
2021
Q3 		$2.98M Buy
+165,952
New +$3.43M ﹤0.01% 3820

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs's CLYM Position: Q2 2026 in Review

Goldman Sachs reduced its Climb Bio (CLYM) stake by 45% in Q2 2026, selling an estimated $689K and leaving 83,230 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #5146.

Goldman Sachs first reported a position in CLYM in Q3 2021 and has held it in 12 quarters since. The position peaked at $2.98M in Q3 2021. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Goldman Sachs held 83,230 shares of Climb Bio worth $1.09M as of Q2 2026.
  • Goldman Sachs sold 66,740 Climb Bio shares in Q2 2026, an estimated $689K.
  • Climb Bio made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5146 holding.
  • Goldman Sachs first reported a position in Climb Bio in Q3 2021 and has held it in 12 quarters since.
  • Goldman Sachs's Climb Bio position peaked at $2.98M in Q3 2021.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.